Document:

Exhibit
10.14

 

 

June
19, 2017

 

Dear
Philippe Goix, PhD, MBA,

 

We
are pleased to extend to you an offer of employment with Avant Diagnostics, Inc. (AVDX). (the “Company”) as set forth
below. This written agreement supersedes and replaces any prior agreements, representations or understandings, whether written,
oral or implied, between you and the Company. The Company initially wishes to hire you as Chief Executive Officer (CEO)
upon funding of an initial total $500,000 investment to be made by Infusion 51a LP together with Asia America Alliance
Limited (Asia America) . This employment agreement will be for the purposes of preparing the current Theralink business inside
Avant for commercialization, as well as assisting Dominick & Dickerman, the investment bank the Company intends to retain
for the raising of capital, to raise an additional $2,000,000 investment. Upon closing that additional $2,000,000 capital raise,
you will be tasked with adding the Precision Health Care Solutions medical technology business model to the Avant platform. Any
references in this Agreement to “you”, the “CEO”, or the “Executive” refer to you.

 

1.  Title
and Duties. You are being offered a full-time, exempt position as the Company’s Chief Executive Officer (CEO),
located at the Company’s offices in Gaithersburg, MD. Your duties include, but are not limited to setting and leading the
Company’s strategic plan of record and annual operating plans. As the Company’s Chief Executive Officer you will lead
the development and execution of strategic business, product, operations, sales, marketing and business development activities.
Your responsibilities will include leadership of Company resources resulting in successful attainment of revenue objectives set
by the Company.

 

You
will lead Company activities for the purpose of evaluating and implementing best business practices intended to further the goals
of the Company. As the most senior constructive and productive leader in the Company, you will be expected to lead by example
by setting high standards of excellence and integrity in all your endeavors, including leadership, planning, and communication,
in all your internal and external relationships with colleagues, partners, vendors and other third parties.

 

In
addition, the CEO’s duties will be to work with shareholders Asia America and International Infusion (and their respective
affiliates) to identify and nominate key industry experts to serve on the Company’s board of directors, and implement appropriate
corporate governance policies for the Company.

 

2.  Commencement
of Employment. The commencement date of your employment will be on the date the Company closes on the first contemplated
$250,000 investment led by Infusion 51a, estimated to close on or around June 20, 2017, provided that you sign, date and return
this offer letter indicating your acceptance.

 

3.  Compensation
and Benefits. As compensation for your services, you will be paid an annual salary of $120,000.00 upon execution of this
agreement, paid at the rate of $10,000 per month. You will also be entitled to a $15,000 signing bonus, and reimbursement for
accrued travel expenses incurred during the CEO recruitment process, approximately $4,500 for which receipts have been submitted.
Upon the Company raising at least an additional $1,750,000.00 (through [a] an additional $250,000 as contemplated in the existing
term sheet with Infusion and Asia America and [b] at least an additional $1.5 million funds to advance the Company’s business
goals), your salary will increase to $240,000 annually that will be paid at the rate of $20,000.00 per month. Upon the Company
listing its common shares on the NASDAQ or NYSE and an additional capital raise of $5M beyond the above mentioned $1,750,000.00,
your salary will increase to $360,000 per year, paid at the rate of $30,000 per month. All forms of compensation paid to you by
the Company are subject to reduction to reflect applicable withholding and payroll taxes and other deductions as required by law.
In addition, you will be eligible for the following:

 

a.  Paid
Time Off. You will be eligible to accrue paid time off according to the Company’s paid time off policy that will
be updated upon the Company’s Board of Directors’ first meeting immediately following your appointment.

 

    	 	1	 

     

    

 

b.  D&O
Insurance. As officer of the Company you will be provided with D&O insurance benefits.

 

b.  Health
Care Benefits. You will be eligible to participate in the Company’s group benefit plans effective as of the date
such plans are agreed to by the Company’s Board of Directors. Currently, the Company does not offer a healthcare benefit
plan.

 

4.
Performance Bonus. 

 

a.
Upon the Company raising an additional $1.5 million, which does not include the Company’s $500,000 financing round with
Asia America and International Infusion or its affiliates (“Infusion”), you will be awarded a cash bonus equal to
the following table:

 

	 	Closing Date of $1.5 Million Raised	 	Cash Bonus Awarded	 
	 	Within 3 months of the execution of this Agreement	 	$	50,000	 
	 	Within 5 months of the execution of this Agreement	 	$	40,000	 
	 	Within 7 months of the execution of this Agreement	 	$	30,000	 

 

b.
Subject to the agreed upon specific milestones, including but not limited to profit targets, to be approved in the future by the
Compensation Committee of the Company’s Board of Directors, you will be eligible to receive a performance bonus of up to
30% of your base salary.

 

5.
  Equity Compensation. Subject to further approval of the Company’s
Board of Directors, you will be granted an option to purchase up to 22 million shares of the Company’s Common Stock, subject
to mutually agreed upon time milestones and success-based milestones, as described below. The exercise price per share will be
equal to the fair market value per share on the date the option is granted. The options will be granted at the closing of the
initial $500,000 investment into the Company by Infusion and Asia America. The options will be subject to the terms and conditions
applicable to options granted under the Company’s to-be-created Equity Incentive Plan (the “Plan”), as described
in the Plan and the applicable Stock Option Agreement:

 

		●	Time
                                         Milestones (up to 10 million options): You will vest in 2.5 million of the option
                                         shares after 12 months of continuous service, and the 7.5 million vest in equal quarterly
                                         installments over the following 12 quarters of continuous service, as described in the
                                         applicable Stock Option Agreement;

 

    	 	2	 

     

    

 

		●	Success
                                         Milestones (up to 12 million options): In addition, an additional 12M options will
                                         vest based upon mutually agreed upon corporate milestones including fund raising and
                                         NASDAQ or NYSE listing. Eligibility for equity compensation and/or participation in any
                                         stock option plan shall not be construed as any assurance of continuing employment for
                                         any particular period of time. This will be along the following terms:

 

		a)	2,000,000
                                         options upon raise of $1.5 million funding within 90 days of execution of this agreement;

 

		b)	10,000,000
                                         options upon listing on the NASDAQ or NYSE;

 

		c)	Upon
                                         listing to the NYSE or NASDAQ, your total compensation will be reviewed by the Compensation
                                         Committee of the Board of Directors;

 

		d)	Upon
                                         accomplishment of the $1.5 million fundraising, the Compensation Committee of the Board
                                         of Directors will meet, no sooner than six months from the date of this agreement, and
                                         establish specific milestones, including but not limited to operational and profit targets
                                         and benchmarks which will be utilized in granting additional equity option grants to
                                         CEO.

 

6.  Severance
Terms. Severance term conditions, including any acceleration of equity compensation will be negotiated with the Company’s
Compensation Committee of the Board of Directors upon successful achievement of the Company’s common stock listing on NASDAQ
or NYSE.

 

7.  Termination
of Employment. Employment with the Company is for no specific period of time. Your employment with the Company will be
“at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with
or without cause. Any contrary representations that may have been made to you are superseded by this offer. Although your job
duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time
to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you
and the Board of Directors of the Company.

 

Either
party may terminate the employment agreement. The Company may terminate the Executive’s employment for any reason or for
no reason and with or without Cause (as defined herein below).

 

		a)	Termination
                                         by the Company for Cause. The Company may terminate the Executive’s employment
                                         at any time for Cause. “Cause” means one or more of the following
                                         events: (i) the Executive’s commission of a felony or other crime, in each case
                                         involving moral turpitude; (ii) the Chief Executive Officer’s commission of any
                                         other act or omission involving fraud or intentional deceit with respect to the Company
                                         or any of its affiliates or any of their directors, stockholders, partners or members;
                                         (iii) any act or omission by the Chief Executive Officer involving dishonesty that causes
                                         material injury to the Company or any of its affiliates or any of their directors, stockholders,
                                         partners or members; (iv) willful misconduct by the Chief Executive Officer with respect
                                         to the Company or any of its subsidiaries; (v) any breach of a fiduciary duty owed by
                                         the Chief Executive Officer to the Company or its stockholders or the Chief Executive
                                         Officer’s contractual breach of this Agreement or any other agreement referred
                                         to herein (including the Proprietary Information and Inventions Agreement), provided
                                         that if such breach is reasonably curable, failure to cure such breach within ten (10)
                                         business days following the delivery written notice from the Company describing such
                                         breach; or (vi) the Chief Executive Officer’s continuing failure to perform assigned
                                         duties after receiving written notification of the failure from the Company and a period
                                         of at least ten (10) business days following the delivery written notice to cure such
                                         failure.

 

    	 	3	 

     

    

 

		b)	If
                                         the Company terminates the Executive’s employment for Cause, the Executive shall
                                         have no right to receive any unvested equity compensation under Section 5 or benefit
                                         hereunder on and after the effective date of the termination of employment, except that
                                         the Executive shall be entitled to receive the Executive’s Annual Salary through
                                         the date of termination and any other benefits that are earned and accrued under this
                                         Agreement prior to the date of termination, and the Executive shall be entitled to receive
                                         reimbursement of expenses incurred prior to the date of termination that are reimbursable
                                         under this Agreement.

  

8.  Employee
Inventions Assignment and Confidentiality Agreement. As an employee of the Company, you will have access to certain confidential
information of the Company and you may, during the course of your employment, develop certain information or inventions that will
be the property of the Company. As a condition of your employment, you are required to sign and return the attached Employee Inventions
Assignment and Confidentiality Agreement (“EIAC Agreement”). Your execution of this offer letter shall be deemed to
be your agreement to and acceptance of the attached EIAC Agreement even if for any reason you do not sign such EIAC Agreement.
We wish to impress upon you that we do not want you to, and we hereby direct that you not, bring with you any confidential or
proprietary material of any former employer, or violate any other obligations you may have to any former employer.

 

9.  Indemnification.
The Executive shall be entitled to indemnification in all instances in which the Executive is acting within the scope
of his authority to the fullest extent permitted by applicable law and not prohibited by the Company’s, GMR or AHR’s
charter and bylaws or operating agreement, as applicable, from and against any damages or liabilities, including reasonable attorney’s
fees; provided, however, that the Executive shall not be entitled to indemnification for damages or liabilities which result from
or arise out of the Executive’s willful misconduct or gross negligence.

  

10.  Existing
Agreements. Executive represents to the Company that the Executive is not subject or a party to any employment or consulting
agreement, non-competition covenant or other agreement, covenant or understanding which might prohibit the Executive from executing
this Agreement or limit the Executive’s ability to fulfill the Executive’s responsibilities hereunder.

  

11.  Survival.
The rights and obligations of the parties under this Agreement, which by their nature would continue beyond the termination
or expiration of this Agreement, shall survive the termination or expiration of this Agreement. The Company’s obligations
hereunder shall not be terminated by reason of any liquidation, dissolution, bankruptcy, cessation of business, or similar event
relating to the Company. This Agreement shall not be terminated by any merger or consolidation or other reorganization of the
Company. In the event any such merger, consolidation or reorganization shall be accomplished by transfer of stock or by transfer
of assets or otherwise, the provisions of this Agreement shall be binding upon and inure to the benefit of the surviving or resulting
corporation or person.

 

    	 	4	 

     

    

 

12.  Arbitration.
Any disputes arising under or in connection with this Agreement shall be resolved by binding arbitration, to be held in
Maryland in accordance with the Commercial Arbitration Rules, as amended from time to time, of the American Arbitration Association
(the “AAA”). The Company and the Executive will each select an arbitrator, and a third arbitrator will be selected
jointly by the arbitrators selected by the Company and the Executive within 15 days after demand for arbitration is made by a
Party. If the arbitrators selected by the Company and the Executive are unable to agree on a third arbitrator within that period,
then either the Company or the Executive may request that the AAA select the third arbitrator. The arbitrators will possess substantive
legal experience in the principle issues in dispute and will be independent of the Company and the Executive. To the extent permitted
by applicable law and not prohibited by the Company’s certificate of incorporation and bylaws, the Company will pay all
expenses (including the reasonable expenses of the Executive, including his reasonable legal fees, if the Executive is the prevailing
party in such arbitration) incurred in connection with arbitration and the fees and expenses of the arbitrators and will advance
such expenses from time to time as required. Except as may otherwise be agreed in writing by the parties or as ordered by the
arbitrators upon substantial justification shown, the hearing for the dispute will be held within 60 days of submission of the
dispute to arbitration. The arbitrators will render their final award within 30 days following conclusion of the hearing and any
required post-hearing briefing or other proceedings ordered by the arbitrators. The arbitrators will state the factual and legal
basis for the award. The decision of the arbitrators will be final and binding and not subject to judicial review and final judgment
may be entered upon such an award in any court of competent jurisdiction, but entry of such judgment will not be required to make
such award effective.

 

Attorneys’
Fees. If litigation shall be brought to enforce or interpret any provision contained herein, the Company, to the extent permitted
by applicable law and not prohibited by the Company’s articles of incorporation and bylaws, shall indemnify the Executive
for the Executive’s reasonable attorneys’ fees and disbursements incurred in such litigation if the Executive is the
prevailing party in such litigation.

  

13.  Governing
Law. This agreement shall be governed by and construed exclusively in accordance with the laws of the state of Maryland
without regard to principles of conflicts of law.

  

14.  Outside
Employment and Competitive Activities. During the period of your full-time employment, you are required to devote your
full-time, best efforts to the interests of the Company. You agree that you will not, without the prior written consent of the
Company, engage in, or encourage or assist others to engage in, any other employment or activity that: (i) would divert from the
Company any business opportunity in which the Company can reasonably be expected to have an interest; (ii) would directly
compete with, or involve preparation to compete with, the current or future business of the Company; or (iii) would otherwise
conflict with the Company’s interests or could cause a disruption of its operations or prospects. Violations of this paragraph
include, but are not limited to, the direct or indirect, ownership, management, operation, control, employment by, or participation
in the ownership, management, operation, or control of any business that is in any way involved with research, development, consulting,
and sale of commercial products relating to the global life sciences, biotechnology, medical device and pharmaceutical industries.
Excepted from this provision is ownership of not more than 10% of the outstanding shares of a publicly traded corporation.

 

15.  Legal
Right to Work. As required by law, your employment by the Company is contingent on you providing timely documentation
as proof of you possessing a legal right to work in the United States.

 

16.  Background
Check. You agree that the Company may undertake a verification of your criminal, education, driving and/or employment
background. This offer can be rescinded based upon data received in the verification.

 

17.  Entire
Agreement. This offer letter, once accepted, constitutes the entire agreement between you and the Company with respect
to the subject matter hereof and supersedes all prior offers, negotiations and agreements, if any, whether written or oral, relating
to such subject matter. You acknowledge that neither the Company nor its agents have made any promise, representation or warranty
whatsoever, either express or implied, written or oral, which is not contained in this agreement for the purpose of inducing you
to execute the agreement, and you acknowledge that you have executed this agreement in reliance only upon such promises, representations
and warranties as are contained herein.

 

18.  Acceptance.
You may indicate your acceptance and agreement with the terms of this offer letter by signing, dating and returning the original
of this offer letter, and the enclosed EIAC Agreement.

 

    	 	5	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have signed their names to this Employment Agreement as of the day and year set forth below.

 

	 	COMPANY:
    
	 	 
	 	

        AVANT
        DIAGNOSTICS, INC,

        a Nevada corporation

	 

    	 	
	Date:
    ____________, 2017	By:  	                
	 	Name:
	 	Title:

 

	 	EXECUTIVE:
    
	 	 	

     
	Date:
    ____________, 2017	By:	   
	 	Name:	Phillippe Goix

 

 

6Exhibit 10.15

 

SEPARATION
AND RELEASE AGREEMENT

 

This
Separation and Release Agreement (the “Agreement”) is by and between Gregg Linn (“Executive”)
and Avant Diagnostics, Inc., a Nevada corporation (the “Company”).

 

WHEREAS,
Executive’s status as an employee and director of the Company will end effective on June 2, 2017 (the “Termination
Date”); and

 

WHEREAS,
Executive and the Company desire to assure a smooth and effective transition of Executive’s duties and to wind-up their
employment relationship amicably; and

 

WHEREAS,
the payments and benefits being made available to Executive pursuant to this Agreement are intended to satisfy all outstanding
obligations under that certain Executive Employment Agreement dated October 1, 2014, between Executive and the Company (the “Employment
Agreement”).

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, Executive and the Company, intending
to be legally bound, hereby agree as follows:

 

1.
Termination Date. Executive acknowledges that his status as an employee director and officer of the Company will end on
the Termination Date. Executive understands that this Agreement is only effective if it is executed on or before June 2, 2017.
Executive has seven (7) days after Executive signs this Agreement to revoke it. This Agreement will become effective on the eighth
(8th) day after Executive signed this Agreement, so long as it has not been revoked by Executive before that date (the “Effective
Date”).

 

2.
Separation Payments and Benefits. Without admission of any liability, fact or claim, the Company hereby agrees, subject
to Executive’s timely execution and non-revocation hereof and Executive’s compliance with Executive’s obligations
pursuant to this Agreement and the Surviving Provisions, to provide Executive the severance payments and benefits set forth below:

 

(a)
Severance Payments.

 

i.
The Company shall pay Executive a lump sum cash payment of $30,000 on the Effective Date by wire transfer to such account as
mutually agreed upon between the parties.

 

ii.
On the Effective Date, the Company shall reimburse Executive for expenses paid on behalf of the Company in the amount of $5,378.41
in accordance with the following schedule: (i) $2,500 on the Effective Date and (ii) $2,878.41 to be paid out of the proceeds
of first closing of the next financing of the Company’s equity and/or debt securities to be consummated after the completion
of the Financing (as defined below), by wire transfer to such account as mutually agreed upon between the parties.

 

    	 	-1-	 

     

    

 

iii.
Upon the earlier of: (i) the Company reporting its first net profit on a quarterly basis equal to or exceeding $1,000,000 (as
determined in accordance with Generally Accepted Accounting Principles), (ii) the Company’s commencement of trading any
of its securities on a national securities exchange or (iii) the Company receiving in excess of $2,500,000 in aggregate gross
proceeds from the sale of its securities on or after the Termination Date (including any securities issued in the Financing as
well as the exercise of any derivative securities for cash on or after the Termination Date) (each of (i), (ii) or (iii), a “Triggering
Event”), the Company shall pay Executive a lump sum cash payment of $180,000 within three (3) business days of the date
such Triggering Event occurs.

 

(b) Benefits
Coverage. If Executive is enrolled in the Company’s group medical, vision and/or dental plans on the
Termination Date, Executive may elect to continue Executive’s participation and that of Executive’s eligible
dependents in those plans for a period of time under COBRA. Executive may make such an election whether or not Executive
accepts this Agreement. If Executive timely elects to continue Executive’s participation and/or that of
Executive’s eligible dependents in such plans, Executive shall pay the full premium cost himself. To the extent any
such group plan can be transferred to another entity controlled by Executive, the parties will work in good faith to honor
any requested transfer of such plan at the request of Executive.

 

(c)
Equity Awards. On the Termination Date, the Company shall issue Executive 15,000,000 restricted shares of the Company’s
common stock (“Equity Issue”) in accordance with the terms of that certain restricted stock award agreement, a copy
of which is attached hereto as Exhibit A. The shares of the Company’s common stock issuable to Executive in accordance with
this Section shall vest quarterly over three (3) years from the Termination Date.

 

(d) Lockup
Agreement. Executive acknowledges and agrees that the lock-up agreement, dated May 11, 2016, a copy of which is attached
hereto as Exhibit B (the “Lock-Up Agreement”) is enforceable against Executive in accordance with its
terms and any shares of the Company’s common stock currently held by Executive including the Equity Issue shall be
subject to the provisions of such Lock-Up Agreement on or after the Termination Date.

 

    	 	-2-	 

     

    

 

(e)
Piggyback Registration Rights. Within one (1) year of the Termination Date, the Company shall use its commercially
reasonable efforts to include on the next registration statement the Company files with SEC for a primary offering (excluding
any securities to be included on Form S-4 or S-8) of its equity securities (or on the subsequent registration statement if such
registration statement is withdrawn) such number of shares of the Company’s common stock held by the Executive and/or his
assigns equal to eight percent (8%) of the aggregate value of the securities to be included on such registration statement (the
“Registrable Securities”). Subject to the terms of this Agreement, the Company shall use its commercially reasonable
efforts to keep such registration statement continuously effective under the Securities Act of 1933 (the “Securities
Act”), until the first to occur of: (A) the date that is one (1) year from the date the registration statement is declared
effective by the Securities and Exchange Commission (the “SEC”) and (B) the date that all Registrable Securities
covered by such registration statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume
or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current
public information requirement under Rule 144 (the “Effectiveness Period”). Notwithstanding the registration
obligations set forth in this Section, if the SEC informs the Company that all of the Registrable Securities cannot, as a result
of the application of Rule 415 promulgated under the Securities Act, be registered for resale on a single registration statement,
the Company agrees to promptly inform Executive and use its commercially reasonable efforts to file amendments to any registration
statement as required by the SEC, covering the maximum number of Registrable Securities permitted to be registered by the SEC,
on Form S-1 or such other form available to register for resale the Registrable Securities; provided, however, that
prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the SEC for the registration
of all of the Registrable Securities in accordance with any (i) any publicly-available written or oral guidance of the SEC staff,
or any comments, requirements or requests of the SEC staff and (ii) the Securities Act (collectively, “SEC Guidance”),
including without limitation, Compliance and Disclosure Interpretation 612.09. Notwithstanding any other provision of this Agreement,
if the SEC or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a
particular registration statement (and notwithstanding that the Company used diligent efforts to advocate with the Commission
for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by Executive
as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be
reduced to such amount as allowed under SEC Guidance. In the event of a cutback hereunder, the Company shall give the Executive
at least five (5) business days prior written notice. In the event the Company amends the registration statement in accordance
with the foregoing, the Company will use its commercially reasonable efforts to file with the SEC, as promptly as allowed by the
SEC or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on
Form S-1 or such other form available to register for resale those Registrable Securities that were not registered on any prior
registration statement filed with the SEC. In addition, if any rights granted pursuant to this Section involves the inclusion
of securities in connection with an underwritten offering, and the managing underwriter (or, in the case of an offering that is
not underwritten, an investment banker) shall advise the Company that, in its opinion, the number of securities requested and
otherwise proposed to be included on such registration statement exceeds the number which can be sold in such offering without
adversely affecting the marketability of the offering, the Company will include in such Registration to the extent of the number
which the Company is so advised can be sold in such offering, first, the securities the Company proposes to sell for its
own account on such registration statement and second, the Registrable Securities of the Executive requesting to be included
on such registration statement.

 

    	 	-3-	 

     

    

 

(f)
Voting Standstill for the Series B Preferred Stock. Executive acknowledges and agrees that he is the sole holder of all
shares of the Company’s preferred stock that is outstanding as of the Termination Date (the “Preferred Shares”).
Beginning on the Termination Date through the date the Company sells its equity and/or debt securities for aggregate gross proceeds
equal to at least $400,000 (the “Financing”), which Financing shall occur on or prior to the 60th
calendar day after the Termination Date, Executive will not, directly or indirectly, without the prior written consent of Infusion
51a, LP (“Infusion”), vote, or otherwise exercise and rights associated with, the Preferred Shares.  In
addition, Executive agrees not to sell, transfer, assign, offer, pledge, directly or indirectly, any of Preferred Shares. 
Executive further represents that there is no other class or series of Preferred Stock issued by the Company. Executive
acknowledges and agrees that appropriate remedy at law for a breach or threatened breach of any of the this voting restriction
would be inadequate and, in recognition of this fact, in the event of a breach or threatened breach by Executive it is agreed
that, in addition to its remedy at law, the Company or Infusion shall be entitled, without posting any bond, to equitable relief
in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy
which may then be available. Upon the consummation of the Financing, Executive acknowledges and agrees that all Preferred Shares
shall be cancelled and forfeited and shall have no further force and effect.

 

(g) Theranostics
Litigation. Executive is aware that prior to the Termination Date, he was named as a party to that certain litigation
entitled, John G. Hartwell et al v. Avant Diagnostics, Inc., et. al., Case No. 432180-V (the
“Litigation”), filed in the Circuit Court for Montgomery County, Maryland (the “Court”). Executive
understands and agrees that after the Termination Date, the Company shall take commercially reasonable efforts to settle the
Litigation with the appropriate parties and have such Litigation dismissed from the Court as soon as reasonable practicable.
To the plaintiffs re-commence the Litigation in Court, the Company agrees and acknowledges that it will indemnify Executive
to the fullest extent permitted by law and pursuant to the Surviving Provisions (as defined below) in connection with the
Litigation.

 

(h) Taxes.
Executive understands and agrees that all payments under this Agreement, except for any expense reimbursement, will be
subject to appropriate tax withholding and other deductions, as and to the extent required by law.

 

(i) Sole
Separation Benefit. Executive agrees that the payments and benefits provided by this Agreement are not required under the
Company’s normal policies and procedures and are provided solely in connection with this Agreement. Executive
further acknowledges and agrees that the payments and benefits referenced in this Agreement constitute adequate and valuable
consideration, in and of themselves, for the promises contained in this Agreement.

 

    	 	-5-	 

     

    

 

(j) Continued
Obligations. Executive acknowledges and agrees that Executive shall continue to be subject to, and abide by, Section 6.01
(Competition/Solicitation) and Section 6.02 (Confidential Information) of the Employment Agreement (collectively, the
“Surviving Provisions”), which shall continue to apply and remain in full force and effect. The
Executive further acknowledges and agrees that in order to comply with the Surviving Provisions, from and after the
Termination Date, Executive may not at any time nor in any venue speak about, present or author any materials with respect to
the Company or its products without the Company’s advance written consent, whether at medical, clinical, investor or
analyst presentations or otherwise, except upon request and at the direction of the Company, other than (i) to his legal
counsel or tax or financial advisors, (ii) as required by law or legal process, (iii) to the limited extent necessary to
defend himself against any claims (x) brought by the Company or (y) in relation to his work for the Company, (iv) statements
made by Executive regarding the Company and/or its products that do not breach the Surviving Provisions or Section 6(b)
hereof, or (v) statements made by Executive regarding (a) Executive's former position, titles, achievements, duties or
responsibilities with the Company or any of its subsidiaries, or (b) Executive's role at the Company and/or role with respect
to any Company products on which Executive worked, provided that (x) in the case of clauses (a) and (b), such statements do
not breach any of the Surviving Provisions or Section 6(b) of this Agreement, and (y) in the case of clause (b), such
statements contain only information about the Company or any of its products that is in the public domain or generally known
within the industry. (the foregoing clauses (i) through and including (v), the “Exceptions”)). In
addition, the Executive agrees that, if asked about the Company or its products by a third party having no involvement in
Executive’s performance of his obligations under Section 6(c), Executive will state that he is not an employee of the
Company and, unless permitted by one of the Exceptions (i) – (iii) or (v), will defer the question to the Company for
response. If the Company believes that Executive has breached any provision of this Agreement or the Surviving Provisions,
then it shall provide Executive with written notice of such alleged breach within 30 days after it has knowledge of the
occurrence thereof and shall provide Executive with 30 days to cure such alleged breach (any breach so cured shall not
be deemed a breach of this Agreement or any of the Surviving Provisions). If the Executive breaches this Agreement or any of
the Surviving Provisions, and fails to cure said breach, the Company shall have no further obligation to provide any payments
pursuant to this Agreement, and all unvested stock shall be forfeited.

 

3.
Full Payment; Termination of Employment Agreement. Other than as set forth in Section 2 above, Executive shall not be entitled
to any other payments including but not limited to bonuses, reimbursements, commissions, or other cash or non-cash awards, penalties,
interest or attorneys’ fees, and Executive expressly represents that Executive has been compensated for all monies owed
to Executive from Executive’s employment with the Company. On the Termination Date, all provisions of the Employment Agreement,
other than the Surviving Provisions and Section 9.02 of the Employment Agreement, shall terminate and Executive shall have no
further rights thereunder.

 

    	 	-6-	 

     

    

 

4.
General Release. As a material inducement for the Company to enter into this Agreement, and in exchange for the performance
of the Company’s obligations under this Agreement provided for herein, Executive knowingly and voluntarily waives and releases
all rights and claims, known and unknown, which Executive may have against the Company or any of its respective subsidiaries,
affiliates or successors, or any of their current or former officers, directors, managers, employees, shareholders, agents, insurance
carriers, auditors, accountants, attorneys or representatives (collectively, the “Releasees”), including any
and all charges, complaints, claims, liabilities, obligations, promises, agreements, contracts, controversies, damages, actions,
causes of action, suits, rights, demands, costs, losses, debts and expenses of any kind. This includes, but is not limited to,
any claim to any equity-based or similar type of award or incentive with respect to the Releasees, including any claim for benefits
under any stock option or other equity-based incentive plan of the Releasees (or any related agreement, arrangement or understanding
with any Releasee); any claim to accelerated vesting or post-termination or severance benefits or payments that are or may become
payable under any plan, arrangement, policy and agreement between Executive and the Company, including, without limitation, the
Employment Agreement, each stock option agreement entered into between Executive and the Company and any agreement or policy with
the Company under which Executive benefits, and any claims for employment discrimination, harassment, wrongful termination, constructive
termination, violation of public policy, breach of any express or implied contract, breach of any implied covenant, fraud, intentional
or negligent misrepresentation, emotional distress, defamation, or any other claims, actual or potential, which in any way arise
from or are related to Executive’s relationship with the Company, including, without limitation, relating to Executive’s
compensation, the termination of the employment relationship, or any other conduct of the Company occurring prior to the execution
of this Agreement. This also includes a release of any claims under any federal, state or local laws or regulations, including,
but not limited to Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. § 2000, et seq.; Americans with
Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701
et seq.; Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621, et seq.; Civil Rights Act of 1866, and Civil
Rights Act of 1991; 42 U.S.C. § 1981, et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); regulations
of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; The Family and Medical Leave Act, as amended, 29
U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Executive
Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification
Act, as amended, 29 U.S.C. § 2101 et seq.; the Federal False Claims Act, as amended, 31 U.S.C. §§ 3729
et seq.; the Dodd-Frank Wall Street Reform and Consumer Protection Act; the Arizona Constitution, the Arizona Civil Rights Act,
the Arizona Employment Protection Act, Arizona’s wage and hour statutes, ; and any other federal, state or local laws of
similar effect. Notwithstanding the generality of the foregoing, Executive does not release any claims which Executive may have
to the following (collectively, the “Unreleased Claims”): (i) claims for unemployment compensation or any state
disability insurance benefits pursuant to the terms of applicable state law, (ii) Executive’s right to continued participation
in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA, (iii) Executive’s right
to any payments and benefits under this Agreement (including, without limitation, any of the payments and benefits set forth in
Section 2), (iv) Executive’s right to vested benefits under the benefit plans of any Releasee, (v) Executive’s right
to indemnification pursuant to Section 9.02 of the Employment Agreement and (vi) Executive’s right to bring to the attention
of the Equal Employment Opportunity Commission claims of discrimination; provided, however, that Executive does release Executive’s
right to secure any damages for alleged discriminatory treatment. The matters that are the subject of the releases referred to
in this Section 4 (and, for the avoidance of doubt, excluding any Unreleased Claims) shall be referred to collectively as the
“Released Matters.”

 

    	 	-7-	 

     

    

 

5.
Acknowledgements Related to ADEA. Executive understands and acknowledges that:

 

(a)
This Agreement constitutes a voluntary waiver of any and all rights and claims Executive has against the Releases, or any of them,
as of the date Executive executes this Agreement, for claims arising under the Age Discrimination in Employment Act, 29 U.S.C.
621, et seq.

 

(b)
Executive has waived rights or claims pursuant to this Agreement and in exchange for consideration, the value of which
exceeds payment or remuneration to which Executive was already entitled.

 

(c)
Executive is hereby advised to consult with an attorney of Executive’s choosing concerning this Agreement prior to executing
it.

 

(d)
Executive has been afforded a period of twenty-one (21) days to consider the terms of this Agreement, as required by the
Older Workers Benefits Protection Act, and in the event Executive should decide to execute this Agreement in fewer than
twenty-one (21) days, Executive has done so with the express understanding that Executive has been given and declined the
opportunity to consider this Agreement for a full twenty-one (21) days, and waives the balance of the twenty-one (21) day
period.

 

(e)
Executive may revoke this Agreement at any time during the seven (7) days following the date of execution of this Agreement, and
this Agreement shall not become effective or enforceable until such revocation period has expired. Executive understands that
if Executive does not sign this Agreement or Executive signs and subsequently revokes this Agreement before it becomes effective,
Executive shall not be entitled to any of the payments or benefits provided in Section 2 of this Agreement.

 

6.
Transition; Non-Disparagement; Cooperation; Transfer of Company Property. Executive further agrees that:

 

(a)
Transition. Both parties agree that it shall not make any internal or external communication addressing Executive’s
separation without the other parties consent and agrees that if Company determines to develop and issue any internal or external
communication regarding Executive’s separation, Executive may collaborate with Company regarding said communication.

 

(b) Non-Disparagement.
Executive agrees that Executive shall not at any time disparage or encourage or induce others to disparage the Company, any
of its subsidiaries, or any of their respective past and present, officers, directors, employees, products or services (the
“Company Parties”). The Company agrees that it shall (i) instruct its present directors and officers not
to disparage or encourage or induce others to disparage the Executive or his reputation (together, the
“Executive Parties”) at any time during which they are employed by, or providing services to, the Company,
and (ii) not cause or direct any of its past or present employees or independent contractors to disparage or encourage or
induce others to disparage any of the Executive Parties. For purposes of this Section 6(b), the term “disparage”
includes, without limitation, comments or statements to the press, to the Company’s or any subsidiaries’
employees or to any individual or entity with whom the Executive, the Company or any subsidiary thereof has a business
relationship (including, without limitation, any vendor, supplier, customer or distributor), or any public statement, that in
each case is intended to, or can be reasonably expected to, damage any of the Company Parties or the Executive Parties, as
applicable. Notwithstanding the foregoing, nothing in this Section 6(b) shall prevent any person from making any truthful
statement to the extent, but only to the extent (A) necessary with respect to any litigation, arbitration or mediation in the
forum in which such litigation, arbitration or mediation properly takes place, or (B) required by law, legal process or by
any court, arbitrator, mediator or administrative or legislative body (including any committee thereof) with apparent
jurisdiction over such person.

 

    	 	-8-	 

     

    

 

(c)
Cooperation. Commencing on the date hereof and continuing during the eighteen (18) month period after the Termination Date
(the “Cooperation Period”), Executive agrees to reasonably cooperate with the Company in its efforts to prosecute
or defend itself against any claim, suit, demand or cause of action (not brought by the Company against Executive or by Executive
against the Company) about which Executive has knowledge. Notwithstanding the immediately preceding sentence, following the Termination
Date, (a) the Company shall provide Executive with advance written notice of such required cooperation within a reasonable period
of time prior to the date on which such cooperation will be required, (b) such cooperation shall not create a conflict with any
of Executive’s obligations or duties to his then current employer, (c) such cooperation shall be provided at times and locations,
and in a manner, that are mutually agreed between the Company and Executive, (d) the Executive shall report to, and take direction
from, only the Company’s Chief Executive Officer in providing the cooperation described above and (e) the Company shall
reimburse Executive (in compliance with Code Section 409A) for all reasonable expenses incurred by him in complying with this
Section 6(c), subject to appropriate itemization and substantiation of such expenses.

 

(d)
Return of Company Property. Executive represents that on or before the Termination Date, Executive will return to the Company
all written Confidential Information (as defined in the Employment Agreement) in Executive’s possession (including, but
not limited to, Company-provided credit cards, building or office access cards, keys, computer or other business equipment,
manuals, files, documents, records, software, employee database and other data), and that Executive will not retain any
copies, compilations, extracts, excerpts, abstracts, summaries or other notes of any such manuals, files, documents, records,
software, customer or employee database or other data files, memoranda, records, and other documents, and any other physical
or personal property which are the property of the Company and which Executive had in Executive’s possession, custody
or control, including any computers, cellular phones, tablets, PDAs or similar business equipment; and provided, further,
that if Executive has inadvertently retained non-material Confidential Information or property of the Company
(“Covered Information”), it shall not be a breach of this Agreement or any of the Surviving Provisions if
(i) promptly after becoming aware of his possession of such Covered Information Executive returns it to the Company, (ii)
Executive has not disclosed such Covered Information in violation of the Surviving Provisions, and (iii) no loss or damage
that is more than de minimis has been caused to the Company as a result of Executive’s retention of such Covered
Information. Notwithstanding this Section 6(d), the Company may provide Executive with Confidential Information and Company
property in connection with his obligations under Section 6(c) hereof and Executive acknowledges and agrees that he shall
return all such Confidential Information and Company property within ten (10) days after the end of
Executive’s obligations under Section 6(c) hereof or such earlier date as is requested reasonably in advance in writing
by the Company (with the same procedures to apply regarding the inadvertent retention of Covered Information as set forth in
the immediately preceding sentence).

 

    	 	-9-	 

     

    

 

7.
Executive Representations. Executive warrants and represents that (a) Executive has not filed or authorized the filing
of any complaints, charges or lawsuits against the Company with any governmental agency or court regarding any claims released
in this Agreement, and that if, unbeknownst to Executive, such a complaint, charge or lawsuit has been filed on Executive’s
behalf, Executive will immediately cause it to be withdrawn and dismissed, (b) Executive has reported all hours worked as of the
date of this Agreement and has been paid all compensation, wages, bonuses, commissions, and/or benefits to which Executive may
be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to Executive, except as provided in
this Agreement, (c) Executive has no known workplace injuries or occupational diseases and has been provided and/or has not been
denied any leave requested under the Family and Medical Leave Act or any state law counterpart, (d) the execution, delivery and
performance of this Agreement by Executive does not and will not conflict with, breach, violate or cause a default under any agreement,
contract or instrument to which Executive is a party or any judgment, order or decree to which Executive is subject, (e) Executive
is executing this Agreement voluntarily and without any duress or undue influence on the part or behalf of the Company, with full
understanding of the terms and consequences, (f) upon the execution and delivery of this Agreement by the Company and Executive,
this Agreement will be a valid and binding obligation of Executive, enforceable in accordance with its terms and (g) the Executive
agrees and acknowledges that in executing this Agreement he does not rely and has not relied on any representation or statement
by any of the Company Parties with regard to the subject matter, basis or effect of this Agreement.

 

8.
Governing Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties hereunder
shall be governed by, the laws of New York, without regard to any principles of conflicts of laws.

 

9.
Section 409A. It is intended that each installment of the payments provided hereunder constitute separate “payments”
for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy, to the
greatest extent possible, the exemption from the application of Code Section 409A provided under Treasury Regulation Section 1.409A-1(b)(4)
(as a “short-term deferral”). To the extent that any provision of this Agreement is ambiguous as to its compliance
with Code Section 409A, the provision will be read in such a manner so that all payments hereunder comply with Code Section 409A.
To the extent any expense reimbursement or the provision of any in-kind benefit under this Agreement is determined to be subject
to Code Section 409A, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in
one calendar year shall not affect the expenses eligible for reimbursement, or the amount of in-kind benefits to be provided,
in any other calendar year (except for any lifetime or other aggregate limitation applicable to medical expenses), in no event
shall any expenses be reimbursed after the last day of the calendar year immediately following the calendar year in which Executive
incurred such expenses, and in no event shall any right to reimbursement or the provision of any in-kind benefit be subject to
liquidation or exchange for another benefit.

 

    	 	-10-	 

     

    

 

10.
Non-Admission of Liability. This Agreement and the fact that it was offered are not and shall not in any way be construed
as admissions by the Company that it violated any federal, state or local law, statute or regulation, or that it acted wrongfully
with respect to the Executive or to any other person or entity in any manner. The Company specifically disclaims any liability
to or wrongful acts against the Executive or any other person or entity.

 

11. Non-Admissibility.
Neither this Agreement nor anything in this Agreement shall be construed to be or shall be admissible in any proceeding as
evidence of or an admission by the Company or the Executive of any violation of any state, federal or local laws or
regulations or any rules, regulations, criteria or standards of any regulatory body. This Agreement may be
introduced, however, in any proceeding to enforce the Agreement.

 

12.
Miscellaneous. This Agreement, together with the Surviving Provisions and Section 9.02 of the Employment Agreement, is
the entire agreement between the parties with regard to the subject matter hereof. Executive and the Company acknowledge that
there are no other agreements, written, oral or implied regarding such subject matter, and that neither the Company nor Executive
may rely on any prior negotiations, discussions, representations or agreements regarding the subject matter hereof. Whenever possible,
each provision of this Agreement shall be interpreted in a manner as to be effective and valid under applicable law, but if any
provision shall be held to be prohibited or invalid under applicable law, such provision shall be ineffective only to the extent
of such prohibition or invalidity, without invalidating or affecting the remainder of such provision or any of the remaining provisions
of this Agreement. The Company represents that the Board of Directors of the Company has duly and validly authorized this Agreement.
This Agreement may be modified only in writing, and such writing must be signed by both Executive and the Company and recited
that it is intended to modify this Agreement.

 

13.
Notice: All notices, requests, demands and other communications hereunder to either party shall be in writing and shall
be delivered, either by hand, by facsimile, by overnight courier or by certified mail, return receipt requested, duly addressed
as indicated below or to such changed address as the party may subsequently designate:

 

To
the Company:

 

Avant
Diagnostics, Inc.

8561
East Anderson Drive

Suite
104

Scottsdale,
AZ 85225

Attention:
Chief Executive Officer

 

with
a copy to (which shall not constitute notice):

 

Sheppard,
Mullin, Richter & Hampton LLP

30
Rockefeller Plaza

New
York, New York 10112

Attn:
Stephen A. Cohen, Esq.

Email:
scohen@sheppardmullin.com

 

To
the Executive:

 

Gregg
Linn

10994
East Beck Lane

Scottsdale,
AZ 85225

Email:

 

    	 	-11-	 

     

    

 

14.
Binding Effect: This Agreement shall be binding upon the Parties and upon their dependents, heirs, representatives, executors,
administrators, successors and assigns, and shall inure to the benefit of the Parties and their respective dependents, heirs,
representatives, executors, administrators, successors and assigns.

 

15. No
Presumption. This Agreement shall be construed and interpreted as if all of its language were prepared jointly by
the Executive and the Company. No language in this Agreement shall be construed against a party on the ground that such party
drafted or proposed that language.

 

16. Execution
of Counterparts. This Agreement may be executed in counterparts, but shall be construed as if signed in one
document. Facsimile or electronically transmitted signatures shall be given the same force and effect as original signatures
with the Parties to provide original signatures as soon as practicable.

 

17. Further
Actions. The Company and Executive agree that in case at any time after the Termination Date any further action is
necessary or desirable to carry out the purposes of this Agreement, including any documents requested by any underwriter
or placement agent in connection with any offering of the Company’s equity and/or debt securities, each of the parties
hereto will take such further action (including without limitation, the execution and delivery of such further instruments
and documents) as any other party hereto may reasonably request in order to carry out the intent and accomplish the purposes
of this Agreement and the consummation of the transactions contemplated hereby.

 

(signature
page follows)

 

    	 	-12-	 

     

    

 

IN
WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed and delivered as of the dates indicated below.

 

	 	EXECUTIVE
	 	 
	 	/s/
                                         Gregg Linn
	 	Gregg
Linn

	 	Date:
    June __, 2017
	 	 
	 	COMPANY
	 	 
	 	/s/
                                         Gerald Commissiong
	 	Name:
        Gerald Commissiong
	 	Title:
Executive Director
	 	Date:
June 7, 2017

 

 

-12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]